On January 31, 2024, the Chairman of the Board of Directors, Darkhan Myngbay, and the independent director of the Board, Rakhat Bayzakov, reviewed the 2023 annual reports of the National Holding QazBioPharm and its subsidiaries.

The meeting discussed the main achievements of the Holding and its subsidiaries and reviewed the work plans for 2024.

The work plans of the National Holding QazBioPharm for 2024 are extensive. In the near future, the Holding will continue production of veterinary and medical products. In this regard, the Ministry of Health of the Republic of Kazakhstan plans to place an order for the QazVac vaccine.

Additionally, the Holding intends to expand the range of veterinary medicines and increase production volumes. Special attention will be paid to the quality of the products manufactured.

During the meeting, the heads of the Holding’s subsidiaries highlighted several key issues.

Chairman of the Board Darkhan Myngbay and independent director Rakhat Bayzakov provided specific instructions on the issues raised and shared several recommendations with the management of the Holding and its organizations.